Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +9.56% | +8.16% | -80.70% |
Mar. 28 | Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 20 | Tenax Therapeutics Secures Global Rights for Levosimendan | MT |
Financials (USD)
Sales 2023 | - | Sales 2024 * | - | Capitalization | 7.49M |
---|---|---|---|---|---|
Net income 2023 | -7M | Net income 2024 * | -19M | EV / Sales 2023 | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 |
-0.71
x | P/E ratio 2024 * |
-0.52
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.61% |
1 day | +9.56% | ||
1 week | +8.16% | ||
Current month | -7.63% | ||
1 month | +2.42% | ||
3 months | -83.94% | ||
6 months | -81.72% | ||
Current year | -80.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | Jan. 10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 4.24 | +9.56% | 208,497 |
24-03-27 | 3.87 | +4.31% | 31,764 |
24-03-26 | 3.71 | +0.27% | 75,226 |
24-03-25 | 3.7 | -3.14% | 32,776 |
24-03-22 | 3.82 | -2.55% | 25,185 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-80.70% | 7.49M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |